Intracranial Tumor Control After Immune-Related Adverse Events and Discontinuation of Immunotherapy for Melanoma-Reference-Cited by-同舟云学术

Intracranial Tumor Control After Immune-Related Adverse Events and Discontinuation of Immunotherapy for Melanoma

Published:2020-12 Issue: Volume:144 Page:e316-e325
ISSN:1878-8750
Container-title:World Neurosurgery
language:en
Short-container-title:World Neurosurgery

Author:

Zhang Michael^ORCID,Rodrigues Adrian J.,Bhambhvani Hriday P.^ORCID,Fatemi Parastou,Pollom Erqi L.^ORCID,Gibbs Iris C.,Thomas Reena P.,Soltys Scott G.^ORCID,Hancock Steven L.,Chang Steven D.,Reddy Sunil A.,Gephart Melanie Hayden,Li Gordon

Funder

Bristol Myers Squibb

Novocure

Publisher

Elsevier BV

Subject

Clinical Neurology,Surgery

Reference23 articles.

1. Phase III Trial Comparing Concurrent Biochemotherapy With Cisplatin, Vinblastine, Dacarbazine, Interleukin-2, and Interferon Alfa-2b With Cisplatin, Vinblastine, and Dacarbazine Alone in Patients With Metastatic Malignant Melanoma (E3695): A Trial Coordinated by the Eastern Cooperative Oncology Group

2. Bcl-2 antisense (oblimersen sodium) plus dacarbazine in patients with advanced melanoma: the Oblimersen Melanoma Study Group;Bedikian;J Clin Oncol,2006

3. Randomized phase III study of temozolomide versus dacarbazine in the treatment of patients with advanced metastatic malignant melanoma;Middleton;J Clin Oncol,2000

4. Nivolumab plus ipilimumab or nivolumab alone versus ipilimumab alone in advanced melanoma (CheckMate 067): 4-year outcomes of a multicentre, randomised, phase 3 trial;Hodi;Lancet Oncol,2018

5. Pembrolizumab versus ipilimumab in advanced melanoma (KEYNOTE-006): post-hoc 5-year results from an open-label, multicentre, randomised, controlled, phase 3 study;Robert;Lancet Oncol,2019

Cited by 3 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Systematic literature review and meta-analysis of clinical outcomes and prognostic factors for melanoma brain metastases;Frontiers in Oncology;2022-12-08

2. Quality of Life and Role of Palliative and Supportive Care for Patients With Brain Metastases and Caregivers: A Review;Frontiers in Neurology;2022-02-17

3. Five-year Follow-up of Patients With Head and Neck Cancer Treated With Nivolumab and Long-term Responders for Over Two Years;In Vivo;2022